vs
HANMI FINANCIAL CORP（HAFC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是HANMI FINANCIAL CORP的1.8倍（$127.1M vs $71.2M），再鼎医药同比增速更快（17.1% vs 17.1%），HANMI FINANCIAL CORP自由现金流更多（$203.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 10.4%）
韩美金融（HANMI FINANCIAL CORP）旗下韩美银行是一家总部位于美国加利福尼亚州洛杉矶的社区银行，目前在加州、得州、伊利诺伊州、纽约州、新泽西州和弗吉尼亚州共设有35家分行与8个贷款业务办事处。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
HAFC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.8倍
$71.2M
营收增速更快
ZLAB
高出0.1%
17.1%
自由现金流更多
HAFC
多$230.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
10.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $71.2M | $127.1M |
| 净利润 | $21.2M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 29.8% | -54.6% |
| 净利率 | 29.8% | — |
| 营收同比 | 17.1% | 17.1% |
| 净利润同比 | 20.0% | — |
| 每股收益（稀释后） | $0.70 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAFCZLAB
| Q4 25 | $71.2M | $127.1M | ||
| Q3 25 | $71.0M | $115.4M | ||
| Q2 25 | $65.2M | $109.1M | ||
| Q1 25 | $62.8M | $105.7M | ||
| Q4 24 | $60.8M | $108.5M | ||
| Q3 24 | $58.5M | $101.8M | ||
| Q2 24 | $56.7M | $100.1M | ||
| Q1 24 | $58.4M | $87.1M |
净利润HAFCZLAB
| Q4 25 | $21.2M | — | ||
| Q3 25 | $22.1M | $-36.0M | ||
| Q2 25 | $15.1M | $-40.7M | ||
| Q1 25 | $17.7M | $-48.4M | ||
| Q4 24 | $17.7M | — | ||
| Q3 24 | $14.9M | $-41.7M | ||
| Q2 24 | $14.5M | $-80.3M | ||
| Q1 24 | $15.2M | $-53.5M |
毛利率HAFCZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率HAFCZLAB
| Q4 25 | 29.8% | -54.6% | ||
| Q3 25 | 31.1% | -42.3% | ||
| Q2 25 | 23.2% | -50.3% | ||
| Q1 25 | 28.1% | -53.3% | ||
| Q4 24 | 29.1% | -62.6% | ||
| Q3 24 | 25.5% | -66.6% | ||
| Q2 24 | 25.5% | -76.0% | ||
| Q1 24 | 26.0% | -80.7% |
净利率HAFCZLAB
| Q4 25 | 29.8% | — | ||
| Q3 25 | 31.1% | -31.2% | ||
| Q2 25 | 23.2% | -37.3% | ||
| Q1 25 | 28.1% | -45.8% | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 25.5% | -40.9% | ||
| Q2 24 | 25.5% | -80.2% | ||
| Q1 24 | 26.0% | -61.4% |
每股收益（稀释后）HAFCZLAB
| Q4 25 | $0.70 | $-0.05 | ||
| Q3 25 | $0.73 | $-0.03 | ||
| Q2 25 | $0.50 | $-0.04 | ||
| Q1 25 | $0.58 | $-0.04 | ||
| Q4 24 | $0.58 | $-0.09 | ||
| Q3 24 | $0.49 | $-0.04 | ||
| Q2 24 | $0.48 | $-0.08 | ||
| Q1 24 | $0.50 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $796.4M | $715.5M |
| 总资产 | $7.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HAFCZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
股东权益HAFCZLAB
| Q4 25 | $796.4M | $715.5M | ||
| Q3 25 | $779.5M | $759.9M | ||
| Q2 25 | $762.8M | $791.7M | ||
| Q1 25 | $751.5M | $810.8M | ||
| Q4 24 | $732.2M | $840.9M | ||
| Q3 24 | $736.7M | $667.7M | ||
| Q2 24 | $707.1M | $704.2M | ||
| Q1 24 | $703.1M | $762.2M |
总资产HAFCZLAB
| Q4 25 | $7.9B | $1.2B | ||
| Q3 25 | $7.9B | $1.2B | ||
| Q2 25 | $7.9B | $1.2B | ||
| Q1 25 | $7.7B | $1.2B | ||
| Q4 24 | $7.7B | $1.2B | ||
| Q3 24 | $7.7B | $985.3M | ||
| Q2 24 | $7.6B | $987.4M | ||
| Q1 24 | $7.5B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $206.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $203.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 286.2% | -21.0% |
| 资本支出强度资本支出/营收 | 3.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 9.70× | — |
| 过去12个月自由现金流最近4个季度 | $356.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流HAFCZLAB
| Q4 25 | $206.0M | $-26.0M | ||
| Q3 25 | $146.9M | $-32.0M | ||
| Q2 25 | $-19.0M | $-31.0M | ||
| Q1 25 | $25.8M | $-61.7M | ||
| Q4 24 | $52.6M | $-55.8M | ||
| Q3 24 | $6.7M | $-26.8M | ||
| Q2 24 | $2.1M | $-42.2M | ||
| Q1 24 | $30.0M | $-90.1M |
自由现金流HAFCZLAB
| Q4 25 | $203.7M | $-26.7M | ||
| Q3 25 | $146.4M | $-35.0M | ||
| Q2 25 | $-19.6M | $-33.9M | ||
| Q1 25 | $25.6M | $-63.2M | ||
| Q4 24 | $49.9M | $-58.4M | ||
| Q3 24 | $6.5M | $-28.2M | ||
| Q2 24 | $1.3M | $-42.9M | ||
| Q1 24 | $29.2M | $-91.1M |
自由现金流率HAFCZLAB
| Q4 25 | 286.2% | -21.0% | ||
| Q3 25 | 206.3% | -30.4% | ||
| Q2 25 | -30.0% | -31.1% | ||
| Q1 25 | 40.7% | -59.9% | ||
| Q4 24 | 82.1% | -53.8% | ||
| Q3 24 | 11.1% | -27.7% | ||
| Q2 24 | 2.3% | -42.9% | ||
| Q1 24 | 50.0% | -104.5% |
资本支出强度HAFCZLAB
| Q4 25 | 3.2% | 0.5% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.9% | 2.6% | ||
| Q1 25 | 0.4% | 1.5% | ||
| Q4 24 | 4.3% | 2.4% | ||
| Q3 24 | 0.4% | 1.3% | ||
| Q2 24 | 1.4% | 0.7% | ||
| Q1 24 | 1.4% | 1.1% |
现金转化率HAFCZLAB
| Q4 25 | 9.70× | — | ||
| Q3 25 | 6.66× | — | ||
| Q2 25 | -1.26× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 2.97× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 1.98× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAFC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
